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1. Introduction 
Luteinizing hormone-releasing hormone (LHRH) 
can be rapidly degraded by peptidases present in the 
hypothalamus and the anterior pituitary of the rat 
[l-4]. A specific endopeptidase has been recognized 
which initially cleaves the decapeptide pGlu-His- 
Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 at the 
Gly6-Leu7 bond, yielding the corresponding hexa- 
and tetrapeptide fragments [l-3]. Since LHRH- 
degrading activity is present both at the site of syn- 
thesis and release of LHRH (the hypothalamus) and 
its site of action (the pituitary),it is possible that these 
peptidases play a physiological role in controlling the 
level of the peptide in the body. 
Investigation of the pattern of biodegradation of 
the neurohormone may guide the design and the syn- 
thesis of stable, long-acting LHRH analogues with 
possible, valuable clinical applications. We have 
demonstrated a correlation between the increased 
biological potencies of some LHRH analogues (substi- 
tuted at position 6 by D-amino acids) and their resis- 
tance to enzymic degradation [5]. Here we have syn- 
thesized 3 new LHRH analogues modified at position 
7 by hydrophobic amino acids: [Phe7]-LHRH, 
[Cha7]-LHRH and [cLeu7]-LHRH,and examined their 
biological activity and their stability to enzymic attack. 
Abbreviations: Amino acid derivatives and peptides follow 
the IUPAC-IUB Commission of Biochemical Nomenclature 
and Symbols as outlined in Eur. J. Biochem. (1972) 27, 
201-207andJ.Biol.Chem.(1975)250,3215-3216;Cha, 
cyclohexyl-L&nine; cLeu, cycloleucine; DMF,N,!/‘dimeth- 
ylformamide; DCC,N,iV’dicyclohexylcarbodiimide; Dnp, 
2,4dinitrophenyl 
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2. Materials and methods 
Cyclohexyl-L-alanine was a generous gift of Miles- 
Yeda, Rehovot . 1 -Aminocyclopentane-1 -carboxylic 
acid (cycloleucine) was purchased from Sigma Chem- 
ical Co., St Louis, MO. 
2 .I . Synthesis of fPhe7]-LHRH, / Cha’j-LHRH and 
[cLeu71-LHRH 
Peptides were synthesized using the standard solid- 
phase procedure [6,7]. A chloromethylated copolymer 
of styrene and 1% divinylbenzene (200-400 mesh, 
0.74 mmol Cl/g, Bio-Rad Labs., Richmond, CA) was 
substituted to a level of 0.53 mmol Gly/g. Amino 
acids were then successively coupled, as their P-t- 
butyloxycarbonyl derivatives to the glycine-resin by 
activation with DCC [6,7]. Sidechain functions were 
protected as follows: histidine with Nim-Dnp; serine 
with 0-benzyl; tyrosine with 0-benzyl; arginine with 
fl-nitro. Cleavage of the protected peptides from the 
resin was achieved by reaction with a saturated solu- 
tion of ammonia in methanol (2 days at 4°C). Under 
these conditions, the Nim-Dnp protecting group of 
histidine was also removed. Treatment of the cleaved 
products with liquid HF containing 10% anisole (1 h 
at 0°C) [8] resulted in removal of all other protecting 
groups. 
The crude peptides were purified by preparative 
high-voltage paper electrophoresis (Whatman no. 3 
paper, 60 min at 60 V/cm) in pyridine-acetate buffer 
(pH 3 S); the overall yield of synthesis being 48%, 
45% and 40% for [Phe7]-LHRH, [Cha7]-LHRH and 
[cLeu7]-LHRH, respectively. 
2.2. Biological assay 
The peptide analogues were tested for their LH- 
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Volume 123, number 2 FEBS LETTERS January 1981 
releasing activity [9]. Pituitaries from 12day-old 
female rats were incubated in 1 ml Krebs-Ringer 
bicarbonate containing 1 mg glucose/ml (KRBC, 
pH 7.4), for 2 h at 37°C under an atmosphere of 95% 
O1 :5% COZ. This medium was then decanted and sub- 
stituted by 1 ml KRBG containing LHRH or an LHRH 
analogue (1 X 10-9-5 X 10c7 M), and incubation was 
continued for 90 min. Aliquots of the medium were 
then analysed for LH by radioimmunoassay, using the 
kit kindly supplied by the National Institute of 
Arthritis and Metaboiism and Digestive Diseases 
(NIAMDD), Rat Pituitary Hormone Program. 
2.3. Enzyme preparation 
Anterior pituitaries (-9 mg each) from 5 rats were 
detached immediately after decapitation and immersed 
in a Thomas homogenizing vessel containing 1 ml 
phosphate-buffered saline (PBS, pH 6.9). The tissue 
was homogenized (10 strokes) using a teflon pestle, 
and then centrifuged for 10 min at 17 000 X g. The 
resulting supernatant was adjusted by addition of PBS 
to 30 mg wet wt tissue/ml. 
2.4. Degradation reaction 
Degradation was performed essentially as in [I]. 
Briefly, LHRH or its analogue (500 ng) was incubated 
LHRH: pGlu-HIS-Trp-SW-Tyr-Gly-Leu- Arp-Pro-GIyNH, 
kyclohexylolonyl’~ LHRH: . . , Gly - 
~phenylala”yl’l LHRH: . . Gly - 
~cycloleucyl’~ LHRH: . . . Gly - 
Fig.1. LHRH analogues modified at position 7. 
in I ml final vol. PBS with enzyme preparation equiv- 
alent to 3,lS and 0.75 mg tissue. The reaction was 
allowed to proceed for 20 min at 37’C and was termi- 
nated by placing the tubes in boiling water for 3 min. 
The tubes were centrifuged for 10 min at 3000 X g 
and the residual LHRH in the supernatant was deter- 
mined by radioimmunoassay [lo]. 
Table 1 
Amino acid analyses and electrophoretic mobilities of LHRH and its analogues 
LHRH’ [Phe’]-LHRH [Cha71-LHRH [ &xi’]-LHRH 
Electrophoretic 
mobility (RLHRH)’ 1 .oo 
Amino acid 
analysesb Glu 1.02 
His 1.01 
Ser 0.98 
Tyr 1.01 
Cly 2.00 
Arg 1.00 
Pro 0.98 
Leu 1.09 
Phe _ 
Cha - 
cLeu - 
1 .oo 0.96 1.06 
0.95 0.96 0.98 
0.94 0.96 1.03 
0.96 0.94 0.99 
0.95 0.95 0.98 
2.08 2.07 1.97 
0.97 0.99 1.01 
1.00 1.11 1.06 
_ 
1.05 
- 
- 
0.98 
- 
0.91 
a Electrophoresis was performed on Whatman no. 3 paper for 1 h at 60 V/cm in pyridine-acetate 
buffer (pH 3.5) 
b Amino acid analyses were performed on a Spinco-Beckman model 120C amino acid analyzer. The 
peptides assayed were hydrolysed with 6 N HCl containing 4% phenol in evacuated sealed tubes at 
110°C for 20 h. Tryptoph~ was not determined 
c LHRH (kindly donated by Ayerst Research Labs., St Laurent,Canada) was used as a standard 
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3. Results and discussion 
Three analogues of LHRH modified at position 7 
were synthesized by the solid-phase method: [Phe7]- 
LHRH, [Cha7]-LHRH and [cLeu7]-LHRH (fig.1). The 
3 peptides were homogenous as determined by thin- 
layer chromatography, using 3 independent solvent 
systems: (I-butanol:acetic acid:water, 4: 1: 1, by vol.); 
(1-butanol:acetic acid:pyridine:water, 1.5:3:10:12, 
byvol.);(chloroform:2% aceticacid:methanol, 12.4:9, 
by vol.); and by high-voltage paper electrophoresis 
(table 1). Amino acid analyses showed ratios close to 
the theoretical (table 1). 
The LH-releasing activities of [Phe7]-LHRH, 
[Cha7]-LHRH and [cLeu7]-LHRH as tested by the in 
vitro biological assay (see section 2) at several dose 
levels were found to be 50%, 66% and 51% of that of 
LHRH, respectively. 
In the standard pituitary extract degradation assay 
(see section 2), 64% of LHRH was decomposed. The 
relative degradation of the analogues, expressed as a 
percentage of LHRH cleavage under identical condi- 
tions, are as follows: [cLeu7]-LHRH, <3%; [Phe7]- 
LHRH, 18% and [Cha7]-LHRH, 65%. 
The relative stability of [cLeu7] and [Phe7] LHRH 
analogues, and to a much lesser extent that of [Cha’]- 
LHRH, again indicates that indeed the Gly6-Leu7 
bond is the preferred site of enzymic attack. However, 
in contrast to analogues modified at position 6, the 
resistance to enzymic degradation was not accom- 
panied by an increase in biological potency. It is pos- 
sible that the steric hindrance introduced into the 
LHRH molecule by the cyclic moieties at position 7 
(Phe, Cha, cLeu) restricts the peptide’s free rotation, 
preventing it from assuming an ‘active’ conformation 
and thus interfering with the binding to the pituitary 
receptor. 
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